Cerenis Therapeutics Revenue and Competitors

Cerenis Therapeutics is a privately-held pharmaceutical company working to develop novel and innovative HDL based therapies with a multiple product franchise for the treatment of cardiovascular disease. Cerenis has identified and initiated a range of early-stage development initiatives including synthetic and small molecule HDL products that are positioned to represent significant advances in HDL therapy and major commercial opportunities for the company. Cerenis is led by an international management team of seasoned experts in HDL research and product development. Their combined clinical, business, regulatory and manufacturing experience will advance the company's research programs with the goal of expediting novel HDL therapies to market.